营养保健品CDMO市场－全球产业规模、份额、趋势、机会和预测，依剂型、服务、公司规模、地区和竞争格局划分，2020-2030年预测

2024年全球营养保健品CDMO市场规模为351亿美元，预计2030年将以7.90%的复合年增长率成长至553.9亿美元。营养保健品是指源自食品，除提供基本营养外，还能带来其他健康益处的产品，涵盖膳食补充剂和功能性食品。全球营养保健品合约开发与生产组织（CDMO）市场正经历强劲成长，主要驱动因素包括消费者预防保健意识的提高、全球人口老化以及对特殊配方和复杂产品开发日益增长的需求。

主要市场驱动因素

主要市场挑战

主要市场趋势

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：客户之声

第五章：全球营养保健品CDMO市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按剂型（片剂和胶囊、粉末、软胶囊、其他）
  • 依服务项目分类（产品配方及开发、生产及包装、研发、法规遵循、其他）
  • 依公司规模划分（小型公司、中型公司、大型公司）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美营养保健品CDMO市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲营养保健品CDMO市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区营养保健品CDMO市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲营养保健品CDMO市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲营养保健品CDMO市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购（如有）
• 产品发布（如有）
• 最新进展

第十三章：全球营养保健品CDMO市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• Catalent Inc.
• Lonza Group AG
• NUTRASCIENCE LABS Inc
• Robinson Pharma, Inc.
• Health Wright Products, Inc.
• Innovations in Nutrition + Wellness
• INPHARMA SpA
• Aenova Group
• NutraPak USA
• SFI Health Pty Ltd.

第十六章：策略建议

第17章调查会社について・免责事项

The Global Nutraceuticals CDMO Market, valued at USD 35.10 Billion in 2024, is projected to experience a CAGR of 7.90% to reach USD 55.39 Billion by 2030. Nutraceuticals are products derived from food sources that provide health benefits beyond basic nutrition, encompassing dietary supplements and functional foods. The global nutraceuticals Contract Development and Manufacturing Organization (CDMO) market experiences robust growth, primarily driven by increasing consumer awareness of preventative healthcare, an aging global population, and the escalating demand for specialized formulations and complex product development.

Key Market Drivers

The global nutraceutical CDMO market is experiencing substantial expansion, primarily driven by the escalating consumer demand for health and wellness products, alongside an increasing trend of outsourcing manufacturing and development within the nutraceutical sector. Consumers are proactively seeking dietary solutions that offer benefits beyond basic nutrition, a behavior pattern reflected in specific market segments. For instance, according to the International Probiotics Association, in March 2024, the Asia Pacific region contributed USD 3.7 billion to global probiotic supplement sales in 2023, representing 42% of the total. This sustained demand for diverse and specialized nutraceuticals necessitates advanced manufacturing capabilities and formulation expertise many brands often lack internally.

Key Market Challenges

A significant challenge impeding the expansion of the Global Nutraceuticals CDMO Market is the stringent and constantly evolving global regulatory landscape. The necessity for CDMOs to continuously adapt and invest in compliance measures directly hampers market growth by increasing operational complexities and costs. This dynamic environment requires substantial resource allocation for staying abreast of diverse national and international regulations, including ingredient approvals, labeling requirements, and manufacturing standards.

Such continuous investment in regulatory expertise, quality systems, and facility upgrades to meet new guidelines leads to higher overheads, impacting pricing strategies and potentially reducing the competitiveness of CDMOs. For instance, according to the National Association of Manufacturers, in 2022, the average U. S. manufacturer paid over $29,000 per employee per year to comply with federal regulations, calculated in 2023 dollars. This financial burden elevates the barrier to entry for new CDMOs and poses an ongoing strain on existing players, thereby limiting overall market expansion as resources are diverted from innovation or capacity building towards compliance.

Key Market Trends

The increasing consumer demand for tailored health solutions is significantly driving the market through personalized nutrition and custom formulation capabilities. Nutraceutical CDMOs are adapting their development and manufacturing processes to produce bespoke products that cater to individual health profiles, genetic predispositions, and lifestyle choices. This shift necessitates flexible production lines, advanced ingredient sourcing, and expertise in diverse formulations to meet evolving consumer expectations for unique dietary support.

Key Market Players

• Catalent Inc.
• Lonza Group AG
• NUTRASCIENCE LABS Inc
• Robinson Pharma, Inc.
• Health Wright Products, Inc.
• Innovations in Nutrition + Wellness
• INPHARMA S.p.A.
• Aenova Group
• NutraPak USA
• SFI Health Pty Ltd.

Report Scope:

In this report, the Global Nutraceuticals CDMO Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Nutraceuticals CDMO Market, By Dosage Form:

• Tablets & Capsules
• Powder
• Softgel
• Others

Nutraceuticals CDMO Market, By Service:

• Product Formulation and Development
• Manufacturing and Packaging
• Research & Development (R&D)
• Regulatory Compliance
• Others

Nutraceuticals CDMO Market, By Company Size:

• Small Companies
• Mid-Sized Companies
• Large Companies

Nutraceuticals CDMO Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Nutraceuticals CDMO Market.

Available Customizations:

Global Nutraceuticals CDMO Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Nutraceuticals CDMO Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Dosage Form (Tablets & Capsules, Powder, Softgel, Others)
  • 5.2.2. By Service (Product Formulation and Development, Manufacturing and Packaging, Research & Development (R&D), Regulatory Compliance, Others)
  • 5.2.3. By Company Size (Small Companies, Mid-Sized Companies, Large Companies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Nutraceuticals CDMO Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Dosage Form
  • 6.2.2. By Service
  • 6.2.3. By Company Size
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Nutraceuticals CDMO Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Dosage Form
      • 6.3.1.2.2. By Service
      • 6.3.1.2.3. By Company Size
  • 6.3.2. Canada Nutraceuticals CDMO Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Dosage Form
      • 6.3.2.2.2. By Service
      • 6.3.2.2.3. By Company Size
  • 6.3.3. Mexico Nutraceuticals CDMO Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Dosage Form
      • 6.3.3.2.2. By Service
      • 6.3.3.2.3. By Company Size

7. Europe Nutraceuticals CDMO Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Dosage Form
  • 7.2.2. By Service
  • 7.2.3. By Company Size
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Nutraceuticals CDMO Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Dosage Form
      • 7.3.1.2.2. By Service
      • 7.3.1.2.3. By Company Size
  • 7.3.2. France Nutraceuticals CDMO Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Dosage Form
      • 7.3.2.2.2. By Service
      • 7.3.2.2.3. By Company Size
  • 7.3.3. United Kingdom Nutraceuticals CDMO Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Dosage Form
      • 7.3.3.2.2. By Service
      • 7.3.3.2.3. By Company Size
  • 7.3.4. Italy Nutraceuticals CDMO Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Dosage Form
      • 7.3.4.2.2. By Service
      • 7.3.4.2.3. By Company Size
  • 7.3.5. Spain Nutraceuticals CDMO Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Dosage Form
      • 7.3.5.2.2. By Service
      • 7.3.5.2.3. By Company Size

8. Asia Pacific Nutraceuticals CDMO Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Dosage Form
  • 8.2.2. By Service
  • 8.2.3. By Company Size
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Nutraceuticals CDMO Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Dosage Form
      • 8.3.1.2.2. By Service
      • 8.3.1.2.3. By Company Size
  • 8.3.2. India Nutraceuticals CDMO Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Dosage Form
      • 8.3.2.2.2. By Service
      • 8.3.2.2.3. By Company Size
  • 8.3.3. Japan Nutraceuticals CDMO Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Dosage Form
      • 8.3.3.2.2. By Service
      • 8.3.3.2.3. By Company Size
  • 8.3.4. South Korea Nutraceuticals CDMO Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Dosage Form
      • 8.3.4.2.2. By Service
      • 8.3.4.2.3. By Company Size
  • 8.3.5. Australia Nutraceuticals CDMO Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Dosage Form
      • 8.3.5.2.2. By Service
      • 8.3.5.2.3. By Company Size

9. Middle East & Africa Nutraceuticals CDMO Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Dosage Form
  • 9.2.2. By Service
  • 9.2.3. By Company Size
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Nutraceuticals CDMO Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Dosage Form
      • 9.3.1.2.2. By Service
      • 9.3.1.2.3. By Company Size
  • 9.3.2. UAE Nutraceuticals CDMO Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Dosage Form
      • 9.3.2.2.2. By Service
      • 9.3.2.2.3. By Company Size
  • 9.3.3. South Africa Nutraceuticals CDMO Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Dosage Form
      • 9.3.3.2.2. By Service
      • 9.3.3.2.3. By Company Size

10. South America Nutraceuticals CDMO Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Dosage Form
  • 10.2.2. By Service
  • 10.2.3. By Company Size
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Nutraceuticals CDMO Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Dosage Form
      • 10.3.1.2.2. By Service
      • 10.3.1.2.3. By Company Size
  • 10.3.2. Colombia Nutraceuticals CDMO Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Dosage Form
      • 10.3.2.2.2. By Service
      • 10.3.2.2.3. By Company Size
  • 10.3.3. Argentina Nutraceuticals CDMO Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Dosage Form
      • 10.3.3.2.2. By Service
      • 10.3.3.2.3. By Company Size

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Nutraceuticals CDMO Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Catalent Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Lonza Group AG
• 15.3. NUTRASCIENCE LABS Inc
• 15.4. Robinson Pharma, Inc.
• 15.5. Health Wright Products, Inc.
• 15.6. Innovations in Nutrition + Wellness
• 15.7. INPHARMA S.p.A.
• 15.8. Aenova Group
• 15.9. NutraPak USA
• 15.10. SFI Health Pty Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer